Literature DB >> 11532279

Anaphylatoxins and infectious and non-infectious inflammatory diseases.

J Köhl1.   

Abstract

In recent years a plethora of data has accumulated directing toward an important role of polypeptides C3a and C5a and its degradation product C5adesArg, summarized as anaphylatoxins (ATs), in microbial host defense and immune regulation. The ATs exert their various biologic functions by interacting with specific C3a- and C5a-receptors present on cells of myeloid origin, epithelial cells, smooth muscle cells as well as on activated B- and T-cells. Activation of AT receptors mediates signal transduction pathways triggering a variety of proinflammatory events. However, by interacting with the cytokine- and chemokine network C3a and C5a exhibit also anti-inflammatory properties. In this review the focus is on the pathogenetic role of the ATs in sepsis, immune complex disease, delayed type hypersensitivity and asthma. Discussed are data from animal models in which the ATs are blocked by specific C3a or C5a inhibitors or from mice with genetic deletions of the specific receptors of either C3a or C5a/C5adesArg.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532279     DOI: 10.1016/s0161-5890(01)00041-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  44 in total

Review 1.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 2.  Complementing the inflammasome.

Authors:  Martha Triantafilou; Timothy R Hughes; Bryan Paul Morgan; Kathy Triantafilou
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

Review 3.  The role of complement in danger sensing and transmission.

Authors:  Jörg Köhl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

5.  C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease.

Authors:  Nelli Shushakova; Julia Skokowa; Jurriaan Schulman; Ulrich Baumann; Jörg Zwirner; Reinhold E Schmidt; J Engelbert Gessner
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 6.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

7.  Association study of the C3 gene with adult and childhood asthma.

Authors:  Hiroki Inoue; Yoichi Mashimo; Makiko Funamizu; Naoki Shimojo; Koichi Hasegawa; Tomomitsu Hirota; Satoru Doi; Makoto Kameda; Akihiko Miyatake; Yoichi Kohno; Yoshitaka Okamoto; Mayumi Tamari; Akira Hata; Yoichi Suzuki
Journal:  J Hum Genet       Date:  2008-06-20       Impact factor: 3.172

8.  Determining the one, two, three, or four long and short loci of human complement C4 in a major histocompatibility complex haplotype encoding C4A or C4B proteins.

Authors:  Erwin K Chung; Yan Yang; Kristi L Rupert; Karla N Jones; Robert M Rennebohm; Carol A Blanchong; C Yung Yu
Journal:  Am J Hum Genet       Date:  2002-09-10       Impact factor: 11.025

9.  A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis.

Authors:  Kutty Selva Nandakumar; Asa Jansson; Bingze Xu; Niclas Rydell; Parvin Ahooghalandari; Lars Hellman; Anna M Blom; Rikard Holmdahl
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

10.  The structure of OMCI, a novel lipocalin inhibitor of the complement system.

Authors:  Pietro Roversi; Olga Lissina; Steven Johnson; Nurfilza Ahmat; Guido C Paesen; Kerstin Ploss; Wilhelm Boland; Miles A Nunn; Susan M Lea
Journal:  J Mol Biol       Date:  2007-03-30       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.